APPLICATION
NDA020897
TYPE
NDA
ORIGINAL APPROVAL
1998-12-16
LATEST ACTION
2021-03-29
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued
Products
DITROPAN XL · ReferenceDiscontinued
OXYBUTYNIN CHLORIDE 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE · ORAL
DITROPAN XL · ReferenceDiscontinued
OXYBUTYNIN CHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE · ORAL
DITROPAN XL · ReferenceDiscontinued
OXYBUTYNIN CHLORIDE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE · ORAL
Approval history
2000-04-17Labeling · Supplement 8 · standardAP
1999-09-29Manufacturing (CMC) · Supplement 7 · standardAP
1999-09-28Manufacturing (CMC) · Supplement 5 · standardAP
1999-07-20Manufacturing (CMC) · Supplement 6 · standardAP
1999-06-30Manufacturing (CMC) · Supplement 4 · standardAP
1999-06-09Manufacturing (CMC) · Supplement 1 · standardAP
1999-05-25Manufacturing (CMC) · Supplement 3 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.